Literature DB >> 9286048

Outer membrane vesicle vaccines made from short-chain lipopolysaccharide mutants of serogroup B Neisseria meningitidis: effect of the carbohydrate chain length on the immune response.

S R Andersen1, G Bjune, E A Høiby, T E Michaelsen, A Aase, U Rye, E Jantzen.   

Abstract

Outer membrane vesicle (OMV) vaccines were made from Neisseria meningitidis strain 44/76 and its two short-chain lipopolysaccharide (LPS) mutants, Mu-1 and Mu-4. Only the 44/76 vaccine contained LPS with the host antigen lacto-N-neotetraose. The protein composition of the vaccines was similar. The LPS carbohydrate chain length proved to influence drastic changes in the LPS immunogenicity as well as the outer membrane proteins (OMPs) ability to elicit functional antibodies in mice. Only LPS in the Mu-1 and Mu-4 vaccines were immunogenic, and the 44/76 vaccine differed also by not inducing antibodies to the class 4 OMP. The Mu-1 vaccine, with a LPS carbohydrate chain comprising only two residues of 2-keto-3-deoxy-octonic acid, induced lower bactericidal activity and less antibodies to the class 1 OMP, compared to the two other vaccines. This indicates that LPS of a certain carbohydrate chain length is required for adequate exposure of the class 1 OMP epitopes essential for inducing bactericidal antibodies.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9286048     DOI: 10.1016/s0264-410x(97)00030-3

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  8 in total

1.  Proteomic analysis of outer membranes and vesicles from wild-type serogroup B Neisseria meningitidis and a lipopolysaccharide-deficient mutant.

Authors:  Jeannette N Williams; Paul J Skipp; Holly E Humphries; Myron Christodoulides; C David O'Connor; John E Heckels
Journal:  Infect Immun       Date:  2006-12-11       Impact factor: 3.441

2.  Immune responses against major outer membrane antigens of Neisseria meningitidis in vaccinees and controls who contracted meningococcal disease during the Norwegian serogroup B protection trial.

Authors:  E Wedege; E A Høiby; E Rosenqvist; G Bjune
Journal:  Infect Immun       Date:  1998-07       Impact factor: 3.441

3.  Immunogenicity of outer membrane proteins in a lipopolysaccharide-deficient mutant of Neisseria meningitidis: influence of adjuvants on the immune response.

Authors:  L Steeghs; B Kuipers; H J Hamstra; G Kersten; L van Alphen; P van der Ley
Journal:  Infect Immun       Date:  1999-10       Impact factor: 3.441

4.  Cross-reactive polyclonal antibodies to the inner core of lipopolysaccharide from Neisseria meningitidis.

Authors:  Svein Rune Andersen; Terry Guthrie; Geoffrey R Guile; Jan Kolberg; Sam Hou; Lisa Hyland; Simon Y C Wong
Journal:  Infect Immun       Date:  2002-03       Impact factor: 3.441

5.  The (alpha2-->8)-linked polysialic acid capsule and lipooligosaccharide structure both contribute to the ability of serogroup B Neisseria meningitidis to resist the bactericidal activity of normal human serum.

Authors:  C M Kahler; L E Martin; G C Shih; M M Rahman; R W Carlson; D S Stephens
Journal:  Infect Immun       Date:  1998-12       Impact factor: 3.441

6.  Pathogenesis, Therapy, and Prevention of Meningococcal Sepsis.

Authors:  David S. Stephens; Shanta M. Zimmer
Journal:  Curr Infect Dis Rep       Date:  2002-10       Impact factor: 3.725

7.  Local and systemic antibody responses in mice immunized intranasally with native and detergent-extracted outer membrane vesicles from Neisseria meningitidis.

Authors:  Terry Guthrie; Simon Y C Wong; Bin Liang; Lisa Hyland; Sam Hou; E Arne Høiby; Svein Rune Andersen
Journal:  Infect Immun       Date:  2004-05       Impact factor: 3.441

8.  Isolation of Chlamydia trachomatis and membrane vesicles derived from host and bacteria.

Authors:  Kyla Frohlich; Ziyu Hua; Jin Wang; Li Shen
Journal:  J Microbiol Methods       Date:  2012-08-30       Impact factor: 2.363

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.